Kaplan-Meier plots of EFS and OS in MGZL. Twenty-four patients were prospectively treated with DA-EPOCH-R. Patients were observed for a median of 59 months (range, 7 to 142 months) and results are presented at 3 years. (A) Overall, EFS was 62% (95% CI, 42% to 79%), and (B) OS was 74% (95% CI, 51% to 89%). (C) EFS for patients with ALCs >880 cells per μL (the median) was 83% (95% CI, 55% to 95%), and for <880 cells per μL, it was 42% (95% CI, 19% to 68%), respectively (P = .038). (D) OS for patients with ALCs ≥880 cells per μL was 100% (95% CI, 74% to 100%), and for <880 cells per μL, it was 52% (95% CI, 24% to 78%), respectively (P = .028). (E) EFS for patients without or with tumor-infiltrating DC-SIGN–positive cells was 67% (95% CI, 35% to 88%) and 40% (95% CI, 17% to 69%), respectively (P = .18). (F) OS for patients without or with tumor-infiltrating DC-SIGN–positive cells was 100% (95% CI, 66% to 100%) and 52% (95% CI, 5% to 68%), respectively (P = .0025). (G) EFS for patients with CD15 scores of 0 to 2 vs 3 to 4 was 74% (95% CI, 50% to 90%) and 38% (95% CI, 14% to 69%), respectively (P = .16). (H) OS for patients with CD15 scores of 0 to 2 vs 3 to 4 was 93% (95% CI, 70% to 99%) and 38% (95% CI, 12% to 74%), respectively (P = .032).